Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression.
Journal of comparative effectiveness research June 9, 2025 Kristin Clemens, Amanda Teeple, Benoit Rive et al.
Aim: Estimate the cost-per-remitter with esketamine nasal spray plus an oral antidepressant (ESK NS + OAD) versus quetiapine extended release plus an oral antidepressant (QTP XR + OAD) among adults with treatment-resistant depression (TRD). Materials & methods: An Excel-based model was developed to estimate the cost-per-remitter for ESK NS + OAD and QTP XR + OAD from the perspective of a US...